Valeant Stock

Good News for Valeant Stock Valeant Pharmaceuticals Intl Inc (NYSE:VRX), of which Bill Ackman is a major shareholder, crashed. Ackman, one of the most emblematic figures of Wall Street, held nine percent of Valeant stock though his Pershing Square Holdings hedge fund, according to SEC filings dated March…

Investors sliced Valeant Pharmaceuticals Intl Inc’s (TSE:VRX, NYSE:VRX) value in half last Tuesday. The reason why Valeant’s stock plunged by 51% in a single day is because the Canadian drug giant reported weaker-than-expected fourth-quarter results, cut its 2016 forecast, and raised fears about defaulting on its debt. When…

This Is Big for Valeant Stock These are tough times for hedge fund manager Bill Ackman of Pershing Square Capital Management after the once most coveted hedge fund lost about 15% in 2015, driven by massive losses in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock and Herbalife Ltd. (NYSE:HLF)…

Here’s Why I’m Bullish on VRX Stock  The bets continue on beleaguered biotech stock Valeant Pharmaceuticals International, Inc. (NYSE:VRX) since it became the target of short seller Andrew Left of Citron Research a few weeks ago. Fast forward and we are still without any solid consensus on whether…

New regulations have dramatically altered the rules by which the biotech industry plays, leaving industry stalwart Valeant Pharmaceuticals International, Inc. (NYSE:VRX) struggling to catch up. Does this spell the end for the rally in VRX stock? Let’s take a look. Has Valeant Stock Finally Bottomed? Not Likely These…

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) is in hot water following a scathing report from short-seller Citron Research. The publication questioned the company’s sales practices, comparing the pharmaceutical giant to Enron. After the dust settled, shares of Valeant stock finished the trading session down more than 20% on Wednesday.…

The Growing Trend That Should Terrify Valeant Stockholders Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has been one of the hottest names in the stock market, but aggressive regulators threaten to bring the run in VRX stock to a halt. This week brought more bad news for Valeant stockholders. On…

Here’s Why Investors Should Avoid Valeant Stock Has the great run in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) finally run its course? Today’s chart says “perhaps.” Over the past few years, the Canadian-based company has become one of the world’s biggest biotech players. Valeant doesn’t actually develop any drugs…